SCHEMBL103100

SCHEMBL103100

C#CCCC(=O)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1556234 0.83
SCHEMBL9451456 0.81
SCHEMBL31467887 0.79 CYP1A2 (0.64)
SCHEMBL8188242 0.79 CYP1A2 (0.64)
SCHEMBL1114673 0.79 CYP1A2 (0.64)
SCHEMBL2025525 0.73
SCHEMBL8803 0.73
SCHEMBL9719198 0.73
SCHEMBL8945449 0.73 MAPT (0.39)
SCHEMBL29123190 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250205232-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-06-26 US disclosed
US-20250052765-A1 Nanobody Discovery Platform and Related Methods CARNEGIE MELLON UNIVERSITY 2025-02-13 US disclosed
US-12168009-B2 Modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-12-17 US disclosed
US-11730726-B2 Dimeric immuno-modulatory compounds against cereblon-based mechanisms H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2023-08-22 US disclosed
US-11730726-B2 Dimeric immuno-modulatory compounds against cereblon-based mechanisms H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2023-08-22 US disclosed
US-20230233560-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-07-27 US disclosed
WO-2023111983-A1 NANOBODY DISCOVERY PLATFORM AND RELATED METHODS CARNEGIE MELLON UNIVERSITY (US) 2023-06-22 WO disclosed
US-11426407-B2 Modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-08-30 US disclosed
US-11078214-B2 Monocyclic thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of same DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) 2021-08-03 US disclosed
WO-2021126974-A1 BIFUNCTIONAL AGENTS FOR PROTEIN RECRUITMENT AND/OR DEGRADATION ORIONIS BIOSCIENCES, INC. (US) 2021-06-24 WO disclosed
US-4847303-A UNSATURATED KETONES THE PROCTER & GAMBLE COMPANY (US) 1989-07-11 US disclosed
EP-0322004-A1 Cyclic anti-inflammatory derivatives of di-tert-butylphenol compounds THE PROCTER & GAMBLE COMPANY (US) 1989-06-28 EP disclosed
EP-0321432-A1 Process for the preparation of certain substituted aromatic compounds Norwich Eaton Pharmaceuticals, Inc. (US) 1989-06-21 EP disclosed
EP-0318090-A2 Tert-butyl phenyl compounds as anti-inflammatory agents THE PROCTER & GAMBLE COMPANY (US) 1989-05-31 EP disclosed
US-4734424-A ANTICOAGULANTS E. R. SQUIBB & SONS, INC. (US) 1988-03-29 US disclosed
US-4724236-A FOR TREATING THROMBOEBOLIC DISEASE, BRADYCARDIA OR BRADYARRYTHMIA KARL THOMAE GMBH (DE) 1988-02-09 US disclosed
US-4663336-A ANTICOAGULANTS E. R. SQUIBB & SONS, INC. (US) 1987-05-05 US disclosed
US-4654355-A 7-oxabicycloheptane substituted amide-thioamide prostaglandin analogs E. R. SQUIBB & SONS, INC. (US) 1987-03-31 US disclosed
US-4638012-A 7-oxabicycloheptane α-substituted ketone prostaglandin analogs useful in the treatment of thrombotic disease E. R. SQUIBB & SONS, INC. (US) 1987-01-20 US disclosed
EP-0207684-A2 7-Oxabicycloheptane substituted diamide and its congener prostaglandin analogs E.R. Squibb &amp; Sons, Inc. (US) 1987-01-07 EP disclosed